|
rs1906953
|
|
Osteosarcoma
|
|
0.820 |
GeneticVariation
|
BEFREE |
Survival analysis for rs1906953 showed that the median survival time of osteosarcoma patients with the CC genotype was significantly shorter compared to the CT and TT genotypes; patients carrying CC genotype have apparently got a decrease in their recurrence-free survival time in comparison with patients carrying TT genotype.
|
26276359 |
2016 |
|
rs1906953
|
|
Osteosarcoma
|
|
0.820 |
GeneticVariation
|
BEFREE |
Further analysis showed the association between rs1906953 and OS was independent of gender and age.
|
24984297 |
2014 |
|
rs17206779
|
|
Osteosarcoma
|
|
0.810 |
GeneticVariation
|
BEFREE |
In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown.
|
24984297 |
2014 |
|
rs7591996
|
|
Osteosarcoma
|
|
0.810 |
GeneticVariation
|
BEFREE |
In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown.
|
24984297 |
2014 |
|
rs28934576
|
|
Osteosarcoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Some of the genetic changes identified were in tumor suppressor genes previously identified as altered in osteosarcoma: p53 (arginine→histidine at codon 273 [R273H], R→cysteine at codon 723 [R273C], and tyrosine→C at codon 163 [Y163C]) and retinoblastoma 1 (RB1) (glutamic acid→* at codon 137 [E137*]).
|
22006429 |
2012 |
|
rs28934576
|
|
Osteosarcoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
On the other hand, transfection of p53-R273H into p53 null human osteosarcoma Saos-2 cells down-regulated procaspase-3 level and induced resistance to the drug toxicity and drug-induced apoptosis.
|
17363498 |
2007 |
|
rs7034162
|
|
Osteosarcoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Single-nucleotide polymorphism rs7034162 was associated with metastasis of osteosarcoma in the Chinese population possibly via downregulation of <i>NFIB</i>.
|
31522615 |
2019 |
|
rs7034162
|
|
Osteosarcoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
We identified an SNP, rs7034162, in NFIB significantly associated with metastasis in European osteosarcoma cases, as well as in cases of African and Brazilian ancestry (meta-analysis of all cases: P = 1.2 × 10(-9); OR, 2.43; 95% confidence interval, 1.83-3.24).
|
26084801 |
2015 |
|
rs10208273
|
|
Osteosarcoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown.
|
24984297 |
2014 |
|
rs28934578
|
|
Osteosarcoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Transfection of mutant p53 (R175H) to p53-null osteosarcoma Saos-2 cells suppressed apoptosis induced by doxorubicin (DOX), cisplatin and gamma radiation.
|
15578696 |
2005 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, no evidence of association was observed between prognosis in osteosarcoma and <i>ERCC1</i> rs11615, <i>ERCC1</i> rs3212986, <i>ERCC1</i> rs2298881, <i>ERCC2</i> rs13181, <i>ERCC4</i> rs1800067, and <i>ERCC5</i> rs1047768 polymorphisms.
|
29950854 |
2018 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Haplotype containing the rs1799793-T and rs11615-T alleles was associated with a statistically increased osteosarcoma risk, OR (95% CI) = 1.47 (1.12-1.92).
|
28474168 |
2017 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.
|
28977987 |
2017 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our results suggest that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients.
|
26400354 |
2015 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.
|
26345951 |
2015 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the Cox proportional hazards model, after adjusting for potential confounding factors, we found that individuals carrying CC genotype of ERCC1 rs11615 was associated with decreased risk of death from osteosarcoma, and the HR (95% CI) was 0.43 (0.15-0.93).
|
25755792 |
2015 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our findings suggest that ERCC1 rs11615 and ERCC1 rs2298881 genetic polymorphisms are significantly associated with poor response to chemotherapy and unfavourable survival of osteosarcoma.
|
26339355 |
2015 |
|
rs11615
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Excision repair cross-complementing (ERCC) group 2 (XPD; rs13181 and rs1799793), group 5 (XPG; rs17655) and group 1 (XPA; rs3212986 and rs11615) polymorphisms were analyzed in a group of 130 homogenously treated patients with high-grade osteosarcoma, for association with event-free survival (EFS), using the Kaplan-Meier plots and log-rank test.
|
21826087 |
2012 |
|
rs1799793
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present meta-analysis, we demonstrated that the homozygous variant genotypes in <i>ERCC2</i> rs1799793 and <i>ERCC5</i> rs2296147 were significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR = 0.62, 95% CI = 0.41-0.93, <i>P</i><sub>heterogeneity</sub> = 0.310, <i>I</i><sup>2</sup> = 15.3%, <i>P</i> = 0.020; TT vs CC for rs2296147: HR = 0.42, 95% CI = 0.23-0.78, <i>P</i><sub>heterogeneity</sub> = 0.708, <i>I</i><sup>2</sup> = 0.0%, <i>P</i> = 0.006).
|
29950854 |
2018 |
|
rs1799793
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs1799793
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.
|
30402838 |
2018 |
|
rs1799793
|
|
Osteosarcoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |